Pipeline

Pipeline Overview

We have assembled a robust portfolio of allogeneic, iPSC-derived cell therapies in autoimmune disease and cancer. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
Product iPSC
PLATFORM Allo-Evasion™ Targets Indications Clinical Trial Research Ind-enabling Clinical P1 P2 P3
Autoimmune Diseases
CNTY-101
iNK
1.0
CD19
B-cell-mediated autoimmune diseases B-cell-mediated autoimmune diseases
CALiPSO-1 CARAMEL IIT1
CALiPSO-1 CARAMEL IIT1
CNTY-308
αβ ιΤ
5.0
CD19
B-cell-mediated diseases​
CNTY-341
αβ ιΤ
5.0
CD19 + CD22
B-cell malignancies
Solid Tumors
Solid tumors
iT
5.0
Nectin-4/other
Solid tumors
Undisclosed
Undisclosed
Non-immune effector
5.0
Undisclosed
Undisclosed

Hematologic tumors​

Solid Tumors

Autoimmune Diseases

Undisclosed

1Agreement in place for an investigator-initiated trial (IIT) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg. The CARAMEL trial is expected to commence in mid-2025 following CTA approval.